Acute Respiratory Distress Syndrome (ARDS) has been studied for decades and we have only recently identified interventions to improve survival. The SARS-CoV-2 pandemic resulted in an extraordinary increase in the incidence of ARDS and has highlighted the importance of evidenced-based management. ICU clinicians should understand the importance of existing interventions that improve mortality in ARDS, and the push for personalized management in the field in the years to come.

**Program Goal:**

1. Review pre-COVID literature on ARDS interventions and outcomes
2. Understand how the field has been impacted by the SARS-CoV-2 pandemic
3. Introduce precision medicine in ARDS via phenotyping

**Target Audience:** Critical Care Medicine, Sleep Medicine, Pulmonology Medicine

---

**Financial Disclosure Information:**

Richard Matthay, MD, Course Director for this educational activity, has no relevant financial relationship(s) with ineligible companies to disclose.

Shriram Alapaty, MD, faculty for this educational activity, has no relevant financial relationship(s) with ineligible companies to disclose.

**Accreditation Statement:** Yale School of Medicine is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

**Designation Statement:** Yale School of Medicine designates this Live Activity for a maximum of 1.00 AMA PRA Category 1 Credit(s)™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

**For questions, email** deborah.lovejoy@yale.edu

**For information to register, email** yalepccsm.grandrounds@yale.edu